RXElite RXEI · USD

Its shares trade under the ticker RXEI. It has been listed since 23 July 2007. In the fiscal year to 31 December 2007, it reported revenue of $2.8m and a net loss of $17.2m. At that date it held total assets of $21.3m and shareholders' equity of $12.3m.

RxElite, Inc. is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. The company is headquartered in Meridian, Idaho. The company went IPO on 2007-07-23. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The firm's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Peter WilliamsChairman of the Board, since 2007
• Earl SullivanPresident, Chief Executive Officer$377,927
• Rick SchindewolfSenior Vice President - New Business Development
• Shannon StithVice President - Finance, Chief Accounting Officer, Secretary
• Mr. Mark AuerbachDirector
• Mr. David RectorDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.